Novo Nordisk Total Long Term Liabilities 2010-2024 | NVO

Novo Nordisk total long term liabilities for the quarter ending September 30, 2024 were $10.106B, a 100.3% increase year-over-year.

  • Novo Nordisk total long term liabilities for 2023 were $5.557B, a 6.55% increase from 2022.
  • Novo Nordisk total long term liabilities for 2022 were $5.215B, a 35.2% increase from 2021.
  • Novo Nordisk total long term liabilities for 2021 were $3.858B, a 122.36% increase from 2020.

Novo Nordisk Total Long Term Liabilities 2010-2024 | NVO

  • Novo Nordisk total long term liabilities for 2023 were $5.557B, a 6.55% increase from 2022.
  • Novo Nordisk total long term liabilities for 2022 were $5.215B, a 35.2% increase from 2021.
  • Novo Nordisk total long term liabilities for 2021 were $3.858B, a 122.36% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$692.7B
Johnson & Johnson (JNJ)$368.4B
AbbVie (ABBV)$294.4B
Merck (MRK)$244.2B
Novartis AG (NVS)$211.1B
AstraZeneca (AZN)$197.8B
Pfizer (PFE)$142.2B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B